SYMPAZAN's oppositions filed in EPO
SYMPAZAN Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8765167 | OTTER PHARMS | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2024
(a month ago) | |
| US8603514 | OTTER PHARMS | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(17 days ago) | |
| US11541002 | OTTER PHARMS | Oral film compositions and dosage forms having precise active dissolution profiles |
Jan, 2040
(15 years from now) | |
Sympazan is owned by Otter Pharms.
Sympazan contains Clobazam.
Sympazan has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Sympazan are:
- US8765167
- US8603514
Sympazan was authorised for market use on 01 November, 2018.
Sympazan is available in film;oral dosage forms.
Sympazan can be used as method of treating seizures.
The generics of Sympazan are possible to be released after 31 January, 2040.
Drugs and Companies using CLOBAZAM ingredient
Market Authorisation Date: 01 November, 2018
Treatment: Method of treating seizures
Dosage: FILM;ORAL
More Information on Dosage
SYMPAZAN family patents
